Annoca has developed, validated and deployed a proprietary technology platform based on libraries of highly engineered human cells that enables high-precision and standardized analysis of T-cell biology. Our technology platform rapidly identifies and validates new disease antigens, in addition to identification, characterization and engineering of TCRs in an industrialised process.

Anocca’s own manufacturing facility enables integration of technology-driven analyses into manufacturing control and multiple independent TCR-modified T-cell therapy (TCR-T) clinical programs.
 

THE T-CELL BIOLOGY CHALLENGE

T-cells are the front line of the adaptive immune system. They are responsible for detecting new threats in the body and orchestrating an appropriate immune response. The fundamentals of how T-cells operate inside the body have been established for decades; however, the immense complexity of T-cell immunity has limited the development of therapies that precisely harness or manipulate T-cell responses. Unlocking the immense potential of T-cell biology for treatment of a wide range of diseases requires a high-precision, systematic and industrialised approach to the analysis of T-cell immunity.